Literature DB >> 18030562

Value of 123I-subtraction and single-photon emission computed tomography in addition to planar 99mTc-MIBI scintigraphy before parathyroid surgery.

Francisca H Jorna1, Pieter L Jager, Tjin H Que, Clara Lemstra, John T M Plukker.   

Abstract

PURPOSE: To find out if single-photon emission computed tomography (SPECT) and (123)I-subtraction can enhance the findings of (99m)Tc-methoxyisobutylisonitrile (MIBI) scintigraphy for the preoperative localization of parathyroid (PT) tumors.
METHODS: Among the 111 consecutive patients who underwent preoperative planar (99m)Tc-MIBI scintigraphy for hyperparathyroidism (HPT), 64 underwent delayed SPECT, and 17 underwent (123)I-subtraction. Two independent blinded experts scored the topographical localization, diagnostic confidence, and impact of each diagnostic modality on the surgical strategy.
RESULTS: For adenomas, (99m)Tc-MIBI scintigraphy had a sensitivity of 77% with a positive predictive value (PPV) of 83%. SPECT did not affect the sensitivity or PPV, but it increased the diagnostic confidence and changed the surgical strategy in 21% of the patients. (123)I-subtraction increased the sensitivity from 64% to 82%, but decreased the PPV from 88% to 82%. In hyperplastic glands, (99m)Tc-MIBI scintigraphy had a sensitivity of 47% and a PPV of 95%. When (99m)Tc-MIBI scintigraphy was combined with SPECT and (123)I-subtraction, the results were 44%/10% and 52%/92%, respectively. Both SPECT and (123)I-subtraction decreased the diagnostic confidence.
CONCLUSIONS: Adding SPECT to (99m)Tc-MIBI scintigraphy improved the surgical decision for parathyroid adenomas. The addition of (123)I-subtraction was of limited value. For hyperplastic glands, (99m)Tc-MIBI scintigraphy was relatively ineffective, even with the addition of SPECT or (123)I-subtraction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18030562     DOI: 10.1007/s00595-007-3550-4

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  43 in total

1.  Pre-operative sestamibi-technetium subtraction scintigraphy in primary hyperparathyroidism: experience with 156 consecutive patients.

Authors:  J M Jones; C F Russell; W R Ferguson; J D Laird
Journal:  Clin Radiol       Date:  2001-07       Impact factor: 2.350

2.  Comparison between MR imaging and 99mTc MIBI scintigraphy in the evaluation of recurrent of persistent hyperparathyroidism.

Authors:  M B Gotway; G P Reddy; W R Webb; E T Morita; O H Clark; C B Higgins
Journal:  Radiology       Date:  2001-03       Impact factor: 11.105

3.  Comparison of parathyroid imaging with technetium-99m-pertechnetate/sestamibi subtraction, double-phase technetium-99m-sestamibi and technetium-99m-sestamibi SPECT.

Authors:  C C Chen; L E Holder; W A Scovill; A M Tehan; D S Gann
Journal:  J Nucl Med       Date:  1997-06       Impact factor: 10.057

4.  Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism.

Authors:  E Hindié; P Urenã; C Jeanguillaume; D Mellière; J M Berthelot; V Menoyo-Calonge; D Chiappini-Briffa; A Janin; P Galle
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

5.  Parathyroid 99mTc-sestamibi scintigraphy: dual-tracer subtraction is superior to double-phase washout.

Authors:  William D Leslie; Jacqueline O Dupont; Bohdan Bybel; Karl T Riese
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-13       Impact factor: 9.236

6.  Comparison and histopathological correlation of three parathyroid imaging methods in a population with a high prevalence of concomitant thyroid diseases.

Authors:  A Staudenherz; C Abela; B Niederle; E Steiner; T Helbich; S Puig; K Kaserer; A Becherer; T Leitha; K Kletter
Journal:  Eur J Nucl Med       Date:  1997-02

7.  Parathyroid imaging using simultaneous double-window recording of technetium-99m-sestamibi and iodine-123.

Authors:  E Hindié; D Mellière; C Jeanguillaume; L Perlemuter; F Chéhadé; P Galle
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

8.  Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study)

Authors:  R Taillefer; Y Boucher; C Potvin; R Lambert
Journal:  J Nucl Med       Date:  1992-10       Impact factor: 10.057

9.  Size and P-glycoprotein expression limit 99mTc-tetrofosmin uptake in parathyroid adenomas.

Authors:  W T Huang
Journal:  Nucl Med Commun       Date:  2002-10       Impact factor: 1.690

10.  Technetium-99m sestamibi scintigraphy and helical CT together in patients with primary hyperparathyroidism: a prospective clinical study.

Authors:  F Lumachi; A Tregnaghi; P Zucchetta; M C Marzola; D Cecchin; P Marchesi; F Fallo; F Bui
Journal:  Br J Radiol       Date:  2004-02       Impact factor: 3.039

View more
  2 in total

1.  Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas.

Authors:  Y S Kushchayeva; S H Tella; S V Kushchayev; D Van Nostrand; K Kulkarni
Journal:  Osteoporos Int       Date:  2019-01-31       Impact factor: 4.507

2.  (99m)Technetium Sestamibi-(123)Iodine Scintigraphy Is More Accurate Than (99m)Technetium Sestamibi Alone before Surgery for Primary Hyperparathyroidism.

Authors:  Eeva M Ryhänen; Jukka Schildt; Ilkka Heiskanen; Mika Väisänen; Aapo Ahonen; Eliisa Löyttyniemi; Camilla Schalin-Jäntti; Matti J Välimäki
Journal:  Int J Mol Imaging       Date:  2015-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.